Literature DB >> 10588410

Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia, II: convergent/discriminant validity and diagnostic group comparisons.

M P Hobart1, R Goldberg, J J Bartko, J M Gold.   

Abstract

OBJECTIVE: In a companion article in this issue of the Journal, the authors presented data suggesting that the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) is sensitive to the types of impairments observed in schizophrenia, correlates highly with standard measures of intelligence and memory, and is related to employment status in a group of patients with schizophrenia drawn from a tertiary care research center. The objectives of the current study were 1) to determine if evidence of the convergent validity of the RBANS could be replicated in a diagnostically heterogeneous sample drawn from a public mental health system, 2) to examine the relationship of the RBANS to a broad neuropsychological battery, and 3) to compare the performance of patients with schizophrenia and patients with bipolar disorder on a neuropsychological battery and the RBANS.
METHOD: The RBANS and a standard neuropsychological battery, including the WAIS-III and Wechsler Memory Scale, 3rd ed. (WMS-III), were given to 150 patients drawn from a larger study of vocational rehabilitation.
RESULTS: Correlations of RBANS total scores with WAIS-III and WMS-III variables were highly similar across study groups. The RBANS correlated highly with a composite z score derived from 22 standard measures of IQ, memory, language, motor, attention, and executive function. Principal component analyses of the neuropsychological battery resulted in a six-factor solution: the RBANS correlated most highly with a general ability factor and had limited correlations with measures of motor performance, vigilance, and executive function. Patients with schizophrenia demonstrated greater deficits on the neuropsychological battery and the RBANS than patients with bipolar disorder.
CONCLUSIONS: These data suggest that the RBANS is a useful screening instrument for assessing the severity of cognitive impairment in psychiatric populations.

Entities:  

Mesh:

Year:  1999        PMID: 10588410     DOI: 10.1176/ajp.156.12.1951

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  30 in total

1.  Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial.

Authors:  Douglas L Boggs; Deanna L Kelly; Robert P McMahon; James M Gold; David A Gorelick; Jared Linthicum; Robert R Conley; Fang Liu; James Waltz; Marilyn A Huestis; Robert W Buchanan
Journal:  Schizophr Res       Date:  2011-12-03       Impact factor: 4.939

2.  Cognitive factor structure and invariance in people with schizophrenia, their unaffected siblings, and controls.

Authors:  Dwight Dickinson; Terry E Goldberg; James M Gold; Brita Elvevåg; Daniel R Weinberger
Journal:  Schizophr Bull       Date:  2010-03-29       Impact factor: 9.306

Review 3.  The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia.

Authors:  Corinne Beinat; Samuel D Banister; Marco Herrera; Vivian Law; Michael Kassiou
Journal:  CNS Drugs       Date:  2015-07       Impact factor: 5.749

Review 4.  Psychomotor slowing in schizophrenia.

Authors:  Manuel Morrens; Wouter Hulstijn; Bernard Sabbe
Journal:  Schizophr Bull       Date:  2006-11-08       Impact factor: 9.306

5.  Hippocampal (subfield) volume and shape in relation to cognitive performance across the adult lifespan.

Authors:  Aristotle N Voineskos; Julie L Winterburn; Daniel Felsky; Jon Pipitone; Tarek K Rajji; Benoit H Mulsant; M Mallar Chakravarty
Journal:  Hum Brain Mapp       Date:  2015-05-09       Impact factor: 5.038

6.  Using the repeatable battery for the assessment of neuropsychological status (RBANS) effort index to predict treatment group attendance in patients with schizophrenia.

Authors:  Raeanne C Moore; Taylor Davine; Alexandrea L Harmell; Veronica Cardenas; Barton W Palmer; Brent T Mausbach
Journal:  J Int Neuropsychol Soc       Date:  2012-12-13       Impact factor: 2.892

7.  Age-related decline in white matter tract integrity and cognitive performance: a DTI tractography and structural equation modeling study.

Authors:  Aristotle N Voineskos; Tarek K Rajji; Nancy J Lobaugh; Dielle Miranda; Martha E Shenton; James L Kennedy; Bruce G Pollock; Benoit H Mulsant
Journal:  Neurobiol Aging       Date:  2010-04-03       Impact factor: 4.673

8.  Age-dependent discrepancies between computerized and paper cognitive testing in patients with schizophrenia.

Authors:  Sylvain Grignon; Claire-Anne Grégoire; Myriam Durand; Marie Mury; Dominique Elie; Jean Marc Chianetta
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2008-07-25       Impact factor: 4.328

9.  A brief cognitive assessment tool for schizophrenia: construction of a tool for clinicians.

Authors:  Irene M Hurford; Stephen R Marder; Richard S E Keefe; Steven P Reise; Robert M Bilder
Journal:  Schizophr Bull       Date:  2009-09-23       Impact factor: 9.306

10.  Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia.

Authors:  S Kristian Hill; John A Sweeney; Robert M Hamer; Richard S E Keefe; Diana O Perkins; Hongbin Gu; Joseph P McEvoy; Jeffrey A Lieberman
Journal:  J Int Neuropsychol Soc       Date:  2008-03       Impact factor: 2.892

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.